Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance

Medpace Holdings IncTrade
iShares 10 20 Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while iShares 10 20 Year Treasury Bond ETF trades at $96.56. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

MEDPTLH
Market Cap
$16.90B
Sector
TechnologyFixed Income
52-Week High
$620.59$105.36
52-Week Low
$393.42$96.39
Enterprise Value
$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

iShares 10 20 Year Treasury Bond ETF

TLH trades at $96.57, up 0.19% today, with a bearish technical signal from moving averages and neutral oscillators. Recent dividends include $0.38 (July 2026), $0.36 (June 2026), and $0.41 (May 2026). Key financial ratios like P/E and ROE are unavailable, limiting fundamental clarity. Support and resistance cluster near $96-$97, indicating tight price consolidation amid weak momentum.

The outlook is cautious due to missing financial metrics and bearish technicals. Risks include reliance on dividend stability and macroeconomic pressures from rising yields. Opportunities may arise if fundamentals improve, but current data suggests limited upside without clearer earnings visibility or positive analyst sentiment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About iShares 10 20 Year Treasury Bond ETF

TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.

Read more on TLH